Search Results - "Fujii, Yasutoshi"

Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib by Fujii, Yasutoshi, Ono, Atsushi, Hayes, C. Nelson, Aikata, Hiroshi, Yamauchi, Masami, Uchikawa, Shinsuke, Kodama, Kenichiro, Teraoka, Yuji, Fujino, Hatsue, Nakahara, Takashi, Murakami, Eisuke, Miki, Daiki, Okamoto, Wataru, Kawaoka, Tomokazu, Tsuge, Masataka, Imamura, Michio, Chayama, Kazuaki

“…Background There has been a recent surge in interest in predicting biological effects associated with genomic alterations in order to implement personalized…”
Get full text

Occurrence of Immunoglobulin G4-related Disease during Chemotherapy for Advanced Breast Cancer by Fujii, Yasutoshi, Doi, Mihoko, Yamane, Hiroaki, Morioka, Takehiko, Komichi, Daisuke, Nishisaka, Takashi, Shinozaki, Katsunori

“…Immunoglobulin G4-related disease (IgG4-RD) is defined as an inflammatory lymphoproliferative disorder. The relationship between malignancies and IgG4-RD…”
Get full text

Efficacy of Lusutrombopag for Thrombocytopenia in Patients with Chronic Liver Disease Scheduled to Undergo Invasive Procedures by Nishida, Yuno, Kawaoka, Tomokazu, Imamura, Michio, Namba, Maiko, Fujii, Yasutoshi, Uchikawa, Shinsuke, Ohya, Kazuki, Daijo, Kana, Teraoka, Yuji, Morio, Kei, Fujino, Hatsue, Nakahara, Takashi, Yamauchi, Masami, Hiramatsu, Akira, Tsuge, Masataka, Aikata, Hiroshi, Takahashi, Shoichi, Hayes, C. Nelson, Fukuhara, Takayuki, Tsuji, Keiji, Arataki, Keiko, Nagaoki, Yuko, Aisaka, Yasuyuki, Kamada, Koji, Kodama, Hideaki, Chayama, Kazuaki

“…Objective Lusutrombopag is a thrombopoietin receptor agonist that improves thrombocytopenia in patients with chronic liver disease scheduled to undergo…”
Get full text

Serum interleukin-6 level predicts the prognosis for patients with alcohol-related acute-on-chronic liver failure by Murakami, Serami, Imamura, Michio, Uchida, Takuro, Suehiro, Yosuke, Namba, Maiko, Fujii, Yasutoshi, Uchikawa, Shinsuke, Teraoka, Yuji, Fujino, Hatsue, Ono, Atsushi, Nakahara, Takashi, Murakami, Eisuke, Okamoto, Wataru, Yamauchi, Masami, Kawaoka, Tomokazu, Miki, Daiki, Hayes, Nelson C., Tsuge, Masataka, Aikata, Hiroshi, Ohira, Masahiro, Ohdan, Hideki, Oka, Shiro

“…Aim Heavy alcohol consumption is the most common etiology of acute-on-chronic liver failure (ACLF) in Japan. In some patients, ACLF is associated with a fatal…”
Get full text

Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma by Kinami, Takahiro, Uchikawa, Shinsuke, Kawaoka, Tomokazu, Yamasaki, Shintaro, Kosaka, Masanari, Johira, Yusuke, Yano, Shigeki, Amioka, Kei, Naruto, Kensuke, Yamaoka, Kenji, Fujii, Yasutoshi, Fujino, Hatsue, Nakahara, Takashi, Ono, Atsushi, Murakami, Eisuke, Okamoto, Wataru, Yamauchi, Masami, Miki, Daiki, Tsuge, Masataka, Oka, Shiro

“…Aim Atezolizumab plus bevacizumab combination therapy (Atezo + Beva) is used as the first‐line therapy for unresectable hepatocellular carcinoma (u‐HCC)…”
Get full text

Useful Predictor for Exacerbation of Esophagogastric Varices after Hepatitis C Virus Eradication by Direct-Acting Antivirals by Nagaoki, Yuko, Yamaoka, Kenji, Fujii, Yasutoshi, Uchikawa, Shinsuke, Fujino, Hatsue, Ono, Atsushi, Murakami, Eisuke, Kawaoka, Tomokazu, Miki, Daiki, Aikata, Hiroshi, Hayes, C. Nelson, Tsuge, Masataka, Oka, Shiro

“…To clarify the risk factors for the aggravation of esophagogastric varices (EGVs) after hepatitis C virus (HCV) eradication with direct-acting antiviral (DAA)…”
Get full text

Correction to: Serum interleukin-6 level predicts the prognosis for patients with alcohol-related acute-on-chronic liver failure by Murakami, Serami, Imamura, Michio, Uchida, Takuro, Suehiro, Yosuke, Namba, Maiko, Fujii, Yasutoshi, Uchikawa, Shinsuke, Teraoka, Yuji, Fujino, Hatsue, Ono, Atsushi, Nakahara, Takashi, Murakami, Eisuke, Okamoto, Wataru, Yamauchi, Masami, Kawaoka, Tomokazu, Miki, Daiki, Hayes, Nelson C., Tsuge, Masataka, Aikata, Hiroshi, Ohira, Masahiro, Ohdan, Hideki, Oka, Shiro

Get full text

Lenvatinib activates anti-tumor immunity by suppressing immunoinhibitory infiltrates in the tumor microenvironment of advanced hepatocellular carcinoma by Yamauchi, Masami, Ono, Atsushi, Amioka, Kei, Fujii, Yasutoshi, Nakahara, Hikaru, Teraoka, Yuji, Uchikawa, Shinsuke, Fujino, Hatsue, Nakahara, Takashi, Murakami, Eisuke, Okamoto, Wataru, Miki, Daiki, Kawaoka, Tomokazu, Tsuge, Masataka, Imamura, Michio, Hayes, C. Nelson, Ohishi, Waka, Kishi, Takeshi, Kimura, Mizuki, Suzuki, Natsumi, Arihiro, Koji, Aikata, Hiroshi, Chayama, Kazuaki, Oka, Shiro

“…Background Lenvatinib, a multiple receptor tyrosine kinase inhibitor, might exert antitumor effects via tumor immune modulation. However, changes in the tumor…”
Get full text

Effectiveness of Repeated Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma-Consideration of the Locations of Target Lesions by Yano, Shigeki, Kimura, Tomoki, Kawaoka, Tomokazu, Kinami, Takahiro, Yamasaki, Shintaro, Johira, Yusuke, Kosaka, Masanari, Amioka, Kei, Naruto, Kensuke, Ando, Yuwa, Yamaoka, Kenji, Fujii, Yasutoshi, Uchikawa, Shinsuke, Fujino, Hatsue, Ono, Atsushi, Nakahara, Takashi, Murakami, Eisuke, Okamoto, Wataru, Yamauchi, Masami, Imamura, Michio, Hirokawa, Junichi, Nagata, Yasushi, Aikata, Hiroshi, Oka, Shiro

“…The present study retrospectively evaluated the efficacy of stereotactic body radiation therapy (SBRT), including repeated SBRT, for hepatocellular carcinoma…”
Get full text

Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma by Amioka, Kei, Kawaoka, Tomokazu, Kosaka, Masanari, Johira, Yusuke, Shirane, Yuki, Miura, Ryoichi, Murakami, Serami, Yano, Shigeki, Naruto, Kensuke, Ando, Yuwa, Kosaka, Yumi, Fujii, Yasutoshi, Kodama, Kenichiro, Uchikawa, Shinsuke, Fujino, Hatsue, Ono, Atsushi, Nakahara, Takashi, Murakami, Eisuke, Okamoto, Wataru, Yamauchi, Masami, Imamura, Michio, Mori, Nami, Takaki, Shintaro, Tsuji, Keiji, Masaki, Keiichi, Honda, Yoji, Kouno, Hirotaka, Kohno, Hiroshi, Moriya, Takashi, Naeshiro, Noriaki, Nonaka, Michihiro, Hyogo, Hideyuki, Aisaka, Yasuyuki, Azakami, Takahiro, Hiramatsu, Akira, Aikata, Hiroshi

“…The association between radiological response and overall survival (OS) was retrospectively evaluated in patients treated with lenvatinib as a first-line…”
Get full text

Number of Endoscopic Retrograde Cholangiopancreatography Procedures Required for Short Biliary Cannulation Time by Kawamura, Takuji, Fujii, Yasutoshi, Uno, Koji, Mandai, Koichiro, Yasuda, Kenjiro

“…Background. Several previous studies assessed the competence in endoscopic retrograde cholangiopancreatography (ERCP) using the bile duct cannulation success…”
Get full text

Successful multimodality treatment for advanced hepatocellular carcinoma with tumor thrombosis of the main portal trunk: a case study by Kosaka, Yumi, Kawaoka, Tomokazu, Ogawa, Yutaro, Amioka, Kei, Naruto, Kensuke, Yoshikawa, Yuki, Ando, Yuwa, Suehiro, Yosuke, Yamaoka, Kenji, Fujii, Yasutoshi, Uchikawa, Shinsuke, Ono, Atsushi, Yamauchi, Masami, Imamura, Michio, Chosa, Keigo, Awai, Kazuo, Nagata, Yasushi, Chayama, Kazuaki, Aikata, Hiroshi

“…The overall survival of patients with advanced hepatocellular carcinoma with tumor thrombosis of the main trunk or bilobar branches of the portal vein is…”
Get full text

Sinusoidal obstruction syndrome post-treatment with trastuzumab emtansine (T-DM1) in advanced breast cancer by Fujii, Yasutoshi, Doi, Mihoko, Tsukiyama, Naofumi, Hattori, Yui, Ohya, Kazuki, Shiroma, Noriyuki, Morio, Kei, Morioka, Takehiko, Aikata, Hiroshi, Shinozaki, Katsunori, Chayama, Kazuaki

“…Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate approved for use in the treatment of human epidermal growth factor receptor 2-positive metastatic…”
Get full text

Impact of MAFLD criteria on postoperative recurrence of non-B, non-C HCC by Johira, Yusuke, Nakahara, Takashi, Yamaoka, Kenji, Fujii, Yasutoshi, Uchikawa, Shinsuke, Fujino, Hatsue, Ono, Atsushi, Murakami, Eisuke, Kawaoka, Tomokazu, Miki, Daiki, Tsuge, Masataka, Oka, Shiro

“…This study aimed to clarify the population in whom the presence of metabolic dysfunction-associated fatty liver disease (MAFLD) especially contributes to…”
Get full text

Value of autotaxin for hepatocellular carcinoma risk assessment in chronic hepatitis B patients treated with nucleos(t)ide analogs by Hiyama, Yuichi, Fujino, Hatsue, Namba, Maiko, Fujii, Yasutoshi, Uchikawa, Shinsuke, Ono, Atsushi, Nakahara, Takashi, Murakami, Eisuke, Kawaoka, Tomokazu, Miki, Daiki, Tsuge, Masataka, Oka, Shiro

“…Aim Autotaxin (ATX) is a newly identified liver fibrosis biomarker; however, its clinical usefulness remains unclear. Therefore, we analyzed the changes in…”
Get full text

Real-world efficacy and safety of durvalumab-tremelimumab as second-line systemic therapy after atezolizumab-bevacizumab in unresectable hepatocellular carcinoma by Miura, Ryoichi, Ono, Atsushi, Yano, Shigeki, Amioka, Kei, Naruto, Kensuke, Yamaoka, Kenji, Fujii, Yasutoshi, Uchikawa, Shinsuke, Fujino, Hatsue, Nakahara, Takashi, Murakami, Eisuke, Kawaoka, Tomokazu, Miki, Daiki, Tsuge, Masataka, Hayes, C Nelson, Oka, Shiro

“…The efficacy and safety of immune-checkpoint inhibitors (ICI) for the treatment of unresectable hepatocellular carcinoma are known. We explored ICI…”
Get full text

The presence of vessels encapsulating tumor clusters is associated with an immunosuppressive tumor microenvironment in hepatocellular carcinoma by Zhang, Peiyi, Ono, Atsushi, Fujii, Yasutoshi, Hayes, Clair Nelson, Tamura, Yosuke, Miura, Ryoichi, Shirane, Yuki, Nakahara, Hikaru, Yamauchi, Masami, Uchikawa, Shinsuke, Uchida, Takuro, Teraoka, Yuji, Fujino, Hatsue, Nakahara, Takashi, Murakami, Eisuke, Miki, Daiki, Kawaoka, Tomokazu, Okamoto, Wataru, Makokha, Grace Naswa, Imamura, Michio, Arihiro, Koji, Kobayashi, Tsuyoshi, Ohdan, Hideki, Fujita, Masashi, Nakagawa, Hidewaki, Chayama, Kazuaki, Aikata, Hiroshi

“…Recently, a distinct vascular pattern in hepatocellular carcinoma (HCC) called vessels encapsulating tumor‐forming clusters (VETC) has received attention…”
Get full text

Sodium-glucose cotransporter-2 inhibitors improve FibroScan-aspartate aminotransferase scores in patients with nonalcoholic fatty liver disease complicated by type 2 diabetes by Ogawa, Yutaro, Nakahara, Takashi, Ando, Yuwa, Yamaoka, Kenji, Fujii, Yasutoshi, Uchikawa, Shinsuke, Fujino, Hatsue, Ono, Atsushi, Murakami, Eisuke, Kawaoka, Tomokazu, Miki, Daiki, Yamauchi, Masami, Tsuge, Masataka, Imamura, Michio, Oka, Shiro

“…Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease caused by excessive lipid accumulation in the liver, and its global incidence is…”
Get full text

Time trend of outcomes according to systemic therapy for patients with unresectable hepatocellular carcinoma: A single-institution study by Uchikawa, Shinsuke, Kawaoka, Tomokazu, Murakami, Serami, Miura, Ryoichi, Shirane, Yuki, Johira, Yusuke, Kosaka, Masanari, Fujii, Yasutoshi, Fujino, Hatsue, Ono, Atsushi, Murakami, Eisuke, Miki, Daiki, Hayes, C Nelson, Tsuge, Masataka, Oka, Shiro

“…We have been able to use molecular targeted agents for unresectable hepatocellular carcinoma since 2009, and immune checkpoint inhibitors have been approved in…”
Get full text

Significance of changes in tumor markers in patients treated with durvalumab plus tremelimumab combination therapy as a surrogate marker for tumor response to unresectable hepatocellular carcinoma by Uchikawa, Shinsuke, Kawaoka, Tomokazu, Murakami, Serami, Miura, Ryoichi, Shirane, Yuki, Johira, Yusuke, Kosaka, Masanari, Fujii, Yasutoshi, Fujino, Hatsue, Ono, Atsushi, Murakami, Eisuke, Miki, Daiki, Hayes, C Nelson, Tsuge, Masataka, Oka, Shiro

“…When evaluating response to immune checkpoint inhibitor therapy, the tumor sometimes initially swells before shrinking and ultimately responding, also called…”
Get full text